Painreform Ltd (PRFX)

$0.75

+0.09

(+13.64%)▲

Live

Performance

  • $0.67
    $0.82
    $0.75
    downward going graph

    10.67%

    Downside

    Day's Volatility :18.61%

    Upside

    8.89%

    downward going graph
  • $0.53
    $20.16
    $0.75
    downward going graph

    29.19%

    Downside

    52 Weeks Volatility :97.37%

    Upside

    96.28%

    downward going graph

Returns

PeriodPainreform LtdIndex (Russel 2000)
3 Months
-77.6%
0.0%
6 Months
-87.07%
0.0%
1 Year
-95.24%
0.0%
3 Years
-99.56%
-23.0%

Highlights

Market Capitalization
1.4M
Book Value
-$3.53
Earnings Per Share (EPS)
-36.84
Wall Street Target Price
12.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-195.07%
Return On Equity TTM
-716.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-17.8M
Diluted Eps TTM
-36.84
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-19.74
EPS Estimate Next Year
-12.06
EPS Estimate Current Quarter
-1.1
EPS Estimate Next Quarter
-0.79

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Painreform Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1500.0%

Current $0.75
Target $12.00

Technicals Summary

Sell

Neutral

Buy

Painreform Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Painreform Ltd
Painreform Ltd
6.45%
-87.07%
-95.24%
-99.56%
-99.84%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
0.22%
-11.71%
9.36%
13.47%
21.32%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-5.08%
20.69%
22.01%
36.17%
36.17%
Zoetis Inc.
Zoetis Inc.
-0.16%
32.8%
16.08%
-7.35%
52.85%
Viatris Inc.
Viatris Inc.
2.53%
4.53%
31.84%
-16.06%
-28.03%
Catalent, Inc.
Catalent, Inc.
0.9%
7.56%
42.8%
-54.43%
23.98%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Painreform Ltd
Painreform Ltd
NA
NA
NA
-19.74
-7.17
-1.95
NA
-3.53
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
35.55
35.55
0.27
4.54
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.52
32.52
1.5
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
37.9
37.9
2.64
5.83
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.67
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
3.02
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Painreform Ltd
Painreform Ltd
Buy
$1.4M
-99.84%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.9B
21.32%
35.55
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$45.6B
36.17%
32.52
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$87.6B
52.85%
37.9
26.29%
Viatris Inc.
Viatris Inc.
Hold
$14.0B
-28.03%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
23.98%
211.02
-23.81%

Insights on Painreform Ltd

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 138.4%

  • Vs NBIX

    In the last 3 years, Painreform Ltd has experienced a drawdown of -99.6%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 45.2%

Institutional Holdings

  • Armistice Capital, LLC

    3.93%

  • Virtu Financial LLC

    0.29%

  • Advisor Group Holdings, Inc.

    0.07%

  • UBS Group AG

    0.01%

Company Information

painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.

Organization
Painreform Ltd
Employees
7
CEO
Dr. Ehud Geller Ph.D.
Industry
Health Technology

Discover More

FAQs